Acrivon AB vs Sinopia Biosciences

Acrivon AB vs Sinopia Biosciences, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Acrivon AB is on 43/100 and Sinopia Biosciences on 54/100.

Acrivon AB logo
Acrivon ABView full profile
Try Acrivon AB
Sinopia Biosciences logo
Sinopia BiosciencesBiotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.
Try Sinopia Biosciences

Where each one leads

Acrivon AB

  • domain rating: 30/100 against 10/100
  • funding raised: $10.0M against $2.2M

Sinopia Biosciences

  • our overall score: 54/100 against 43/100

At a glance

MeasureAcrivon ABSinopia Biosciences
What it isAcrivon AB develops targeted therapies for cancer patients by matching drug mechanisms to the biologic drivers of cancer using their proprietary AP3 platform.Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.
CategoryAI Tools & Apps, AI Drug Discovery, Biotech, HealthTechBiotechnology, Drug Discovery, Oncology, Biotech
Sells toBusiness modelB2BB2B
OfferingSoftwarePlatform
Founded20222017
HeadquartersUppsala, SwedenSan Diego, USA
StatusActiveActive

Size, funding and growth

MeasureAcrivon ABSinopia Biosciences
Total funding$10.0M$2.2M
Latest roundSeedGrant
ValuationNot published$1.1B

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureAcrivon ABSinopia Biosciences
StartupHub scoreOur 0-100 rating43/10054/100
Traction35/10032/100
Team60/10070/100
Community15/100Not published
Search visibility5/10015/100
Quality50/10068/100
Agent readinessHow well an AI agent can read and act on the siteD (40/100)D (40/100)
Domain ratingLink authority, 0-10030/10010/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureAcrivon ABSinopia Biosciences
CDNCloudflareNot detected
CMSWordPressSquarespace
FrameworksReactNot detected
AnalyticsGoogle Analytics 4Not detected

Acrivon AB vs Sinopia Biosciences: common questions

Which is better, Acrivon AB or Sinopia Biosciences?

On our 0-100 score Sinopia Biosciences rates higher (54/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.

How do Acrivon AB and Sinopia Biosciences compare on the numbers?

Acrivon AB leads on domain rating (30/100 against 10/100), funding raised ($10.0M against $2.2M). Sinopia Biosciences leads on our overall score (54/100 against 43/100).

Read the full Acrivon AB review and pricing or the Sinopia Biosciences review and pricing. You can also browse other Acrivon AB alternatives we track.